用于II期多臂多阶段研究决策的灵活多指标贝叶斯框架
提出一个基于点估计、不确定性和目标产品概况阈值证据的多指标贝叶斯框架,用于II期多臂多阶段试验的中期决策,包括臂间排序和与内部对照的比较。以结核病新药臂为动机示例的模拟研究显示,即使中间结局与主要结局仅中度相关,每臂30例样本量即可为决策提供足够信心。该框架受到研究伙伴认可,是更高效评估新疗法的实用方法。
要点
- 多指标贝叶斯框架整合点估计、不确定性和目标产品概况阈值证据,支持II期多臂多阶段中期决策。
- 模拟研究显示每臂30例样本量即可为决策提供足够信心,即使中间结局与主要结局仅中度相关。
- 框架用于臂间排序及每个臂与内部对照的比较,受到研究伙伴认可。
核心结论
- 多指标贝叶斯框架可为II期多臂多阶段研究的中期决策提供足够信心,即使样本量低至每臂30例且中间结局与主要结局仅中度相关。
- 该框架对试验设计和决策过程的重新构建受到研究伙伴认可,是更高效评估新疗法的实用方法。
研究设计与样本
- 提出一个基于点估计、不确定性和朝向期望阈值(目标产品概况)证据的多指标贝叶斯框架,用于(1)臂间排序和(2)每个臂与内部对照的比较。
- 以大型公私合作项目针对新型结核病臂为动机示例,通过模拟研究评估框架性能。
主要发现
- 模拟研究显示,多指标框架在每臂样本量低至30例时即可为决策提供足够信心,即使中间结局与主要结局仅中度相关。
临床怎么用
- 作者认为该框架是更高效评估新疗法的实用方法,并已被研究伙伴接受用于II期多臂多阶段研究的中期决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We propose a multi-metric flexible Bayesian framework to support efficient interim decision-making in multi-arm multi-stage phase II clinical trials. Multi-arm multi-stage phase II studies increase the efficiency of drug development, but early decisions regarding the futility or desirability of a given arm carry considerable risk since sample sizes are often low and follow-up periods may be short. Further, since intermediate outcomes based on biomarkers of treatment response are rarely perfect surrogates for the primary outcome and different trial stakeholders may have different levels of risk tolerance, a single hypothesis test is insufficient for comprehensively summarizing the state of the collected evidence. We present a Bayesian framework comprised of multiple metrics based on point estimates, uncertainty, and evidence towards desired thresholds (a Target Product Profile) for (1) ranking of arms and (2) comparison of each arm against an internal control. Using a large public-private partnership targeting novel TB arms as a motivating example, we find via simulation study that our multi-metric framework provides sufficient confidence for decision-making with sample sizes as low as 30 patients per arm, even when intermediate outcomes have only moderate correlation with the primary outcome. Our reframing of trial design and the decision-making procedure has been well-received by research partners and is a practical approach to more efficient assessment of novel therapeutics.
引用
- Dufault SM, Crook AM, Rolfe K, et al. A flexible multi-metric Bayesian framework for decision-making in Phase II multi-arm multi-stage studies. Stat Med. 2023. PMID: 38038137. doi:10.1002/sim.9961
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。